Status:
RECRUITING
Effect of Helmet Type, Home-use Low-level Light Therapy Device for Chemotherapy-induced Alopecia
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Breast Cancer
Chemotherapy-induced Alopecia
Eligibility:
FEMALE
20-75 years
Phase:
NA
Brief Summary
As far as breast cancer is concerned, chemotherapy (CT) is an important treatment. However, there are many adverse effects impairing the patient's quality of life (QOL), in which chemotherapy-induced ...
Eligibility Criteria
Inclusion
- Age: 20 to 75 years
- Informed Consent as documented by signature.
- Able to read and converse in chinese
- Female
- Diagnosis of breast cancer
- They completed chemotherapy no more than 2 weeks
- Treatment with neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy: anthracycline and taxane containing (paclitaxel or docetaxel) chemotherapy regimen.
- life expectancy was at least 6 months.
- Diagnosed with CIA grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE)
Exclusion
- scalp tumor or melanoma
- having any serious mental illness or history, or taking psychotropic drugs
- a medical history of dermatosis
- severe liver and kidney damage
- Pregnancy
- Take any of the following medications for 6 months prior to initiation of the study: topical minoxidil, and spironolactone, and topical calcitriol
- Receiving scalp cooling during chemotherapy
Key Trial Info
Start Date :
August 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT05397457
Start Date
August 17 2022
End Date
December 31 2025
Last Update
February 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Keelung Chang Gung Memorial Hospital
Keelung, Taiwan, 20401